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For more than a decade, investigators have pursued methods to genetically engineer 
natural killer (NK) cells for use in clinical therapy against cancer. Despite considerable 
advances in viral transduction of hematopoietic stem cells and T cells, transduction effi-
ciencies for NK cells have remained disappointingly low. Here, we show that NK cells can 
be genetically reprogramed efficiently using a cGMP-compliant mRNA electroporation 
method that induces rapid and reproducible transgene expression in nearly all trans-
fected cells, without negatively influencing their viability, phenotype, and cytotoxic func-
tion. To study its potential therapeutic application, we used this approach to improve key 
aspects involved in efficient lymphoma targeting by adoptively infused ex vivo-expanded 
NK cells. Electroporation of NK cells with mRNA coding for the chemokine receptor 
CCR7 significantly promoted migration toward the lymph node-associated chemokine 
CCL19. Further, introduction of mRNA coding for the high-affinity antibody-binding 
receptor CD16 (CD16-158V) substantially augmented NK cell cytotoxicity against rit-
uximab-coated lymphoma cells. Based on these data, we conclude that this approach 
can be utilized to genetically modify multiple modalities of NK cells in a highly efficient 
manner with the potential to improve multiple facets of their in vivo tumor targeting, thus, 
opening a new arena for the development of more efficacious adoptive NK cell-based 
cancer immunotherapies.
Keywords: gene therapy, nK cells, nK cell immunotherapy, antibody-dependent cellular cytotoxicity, cellular 
migration
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inTrODUcTiOn
Natural killer (NK) cells are cytotoxic immune cells that play an 
important role in the defense against cancer. They have also been 
shown to induce antitumor responses in settings of hematopoi-
etic stem cell transplantation and in pilot clinical trials utilizing 
adoptive NK cell transfer (1, 2). Several methods to expand 
clinical-grade NK cells have recently been developed that allow 
for multiple injections of a large number of highly cytotoxic NK 
cells. Preliminary data from our ongoing phase I clinical trial have 
established that up to 2.5 × 108 autologous ex vivo-expanded NK 
cells per kilogram can be safely infused into cancer patients, with 
tumor regression observed in some patients (3).
Genetic manipulation of NK cells to improve their persistence, 
tumor-targeting capacity, and the ability to home to disease sites 
in vivo may further enhance the efficacy of NK cell-based cancer 
immunotherapy (4). However, genetic manipulation of NK 
cells has historically proven to be challenging (5). In contrast 
to T cells, viral transduction of NK cells is less efficient and may 
compromise cell viability as summarized in Carlsten and Childs 
(5). Due to the use of viral vectors, this approach also comes 
with regulatory issues, high costs, and the need for specialized 
high-level biosafety laboratory platforms when taken to a clini-
cal setting. Moreover, the predicted relatively short persistence 
of adoptively infused NK cells compared to T cells implies that 
stable transgene expression may not be equally necessary for this 
cell type. Therefore, we investigated mRNA electroporation as 
an alternative method to genetically modify NK cells for clinical 
use. This approach can genetically modify cells without using 
viral vectors, precluding the need for high-level biosafety labo-
ratories. Although preclinical studies have shown that mRNA 
electroporation can be used to genetically modify NK cells (2, 
6), a detailed characterization describing how electroporation 
affects NK cells per  se and how this approach can be used to 
modify multiple modalities on one NK cell, such as tumor tissue 
homing and ability to target antibody-coated tumor cells, to 
further improve NK cell-based cancer immunotherapy has not 
yet been reported.
Here, we present detailed data characterizing the transgene 
expression, viability, proliferative capacity, phenotype, and 
cytotoxic function of ex vivo-expanded human NK cells follow-
ing mRNA electroporation using a cGMP-compliant platform. 
Further, we demonstrate that this approach can be used to 
modify NK cells to improve their homing capacity to chemokines 
expressed in malignant lymphoid tissues and augment their abil-
ity to mediate antibody-dependent cellular cytotoxicity (ADCC). 
Collectively, our data demonstrate that mRNA electroporation 
is an efficient method to genetically modify NK cells, with the 
potential to reprogram multiple NK cell properties that boost 
their antitumor function without incurring any major negative 
effects on this cell population.
MaTerials anD MeThODs
cell lines and reagents
The K562, MM.1S, and CD20+ 721.221 cell lines were obtained 
from ATCC and propagated in RPMI 1640 supplemented 
with 10% heat-inactivated FBS (Sigma-Aldrich) and 2  mM 
glutamine (Life Technologies). The following reagents were 
used: anti-CD56 (NCAM-1), anti-CD3 (UCHT1), anti-CD16 
(3G8), anti-NKG2D (1D11), anti-TRAIL (RIK-2), anti-NKp30 
(p30-15), anti-NKp46 (29A1.4), IgG1 (MOPC21), and Annexin 
V and 7-AAD from Becton Dickinson (BD); anti-KIR2DL1/
DS1 (EB6), anti-KIR2DL2/3/DS2 (GL183), and anti-NKG2A 
(Z199) from Beckman Coulter; the anti-CD107a (H4A3), 
anti-KIR3DL1 (Dx9), anti-CD57 (HCD57), anti-2B4 (C1.7), 
anti-CD34 (581), anti-CCR7 (G043H7), IgG2a (MOPC-173), 
and BV650-streptavidin from Biolegend; the anti-Lir-1 (HP-
F1) from eBioscience; the anti-NKG2C (134591) from R&D 
Systems; LIVE/DEAD viability marker from Life Technologies; 
biotinylated anti-KIR3DL2 (Dx31) from UCSF; rituximab 
(Rituxan) from Genentech; and off-the-shelf eGFP mRNA and 
custom-made CD34, CD16, and CCR7 mRNAs from TriLink 
Biotechnology.
nK cell expansion
Natural killer cells expanded ex vivo for 11–15  days were 
isolated from healthy donor PBMC using the NK cell isola-
tion kit from Miltenyi and combined in G-Rex flasks (Wilson 
Wolf Manufacturing) with irradiated EBV–SMI–LCL cells at 
a ratio of 1:10 in NK cell media [X-VIVO 20 (Lonza) sup-
plemented with 10% heat-inactivated human AB plasma 
(Sigma-Aldrich) and 500  IU/ml of recombinant human IL-2 
(Roche)] (3). The cells were cultured at 37°C and 6.5% CO2. 
Half media was replaced with fresh NK cell media 5 days into 
the expansion. Thereafter, NK cells were counted and adjusted 
to 0.5–1 × 106 cells/ml every 48 h, from day 7 until utilized in 
experiments.
electroporation of nK cells
Natural killer cells were electroporated using the MaxCyte GT® 
Transfection System. In brief, cells were first collected and washed 
in electroporation buffer (HyClone). They were then mixed with 
mRNA in a total volume of 100 μl and transferred to an OC-100 
cuvette. Electroporation was conducted using an optimized 
program for NK cells. The instrument settings for optimized NK 
cell transfection are proprietary to MaxCyte, Inc. Cells were then 
transferred to one well of a 48-well plate and incubated at 37°C 
and 6.5% CO2 for 20 min before being resuspended in NK cell 
media and transferred to culture flasks.
cytotoxicity assay
Natural killer cells were cocultured at a ratio of 1:1 with either 
51Cr-labeled K562 cells or MM.1S cells in a final volume of 200 μl 
in 96-well plates at 37°C and 5% CO2. After 4  h, supernatant 
was harvested onto a Luma plate. Counts were measured using 
a Perkin Elmer 1450 Microbeta Counter and specific target lysis 
was calculated using the following formula: [(NK cell-induced 
51Cr release  −  spontaneous 51Cr release)/(maximum 51Cr 
release − spontaneous 51Cr release) × 100].
nK cell Migration assay
Migration assays were performed using 24-well plates with 
Corning Transwell® inserts. Six hundred microliters of serum-free 
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X-VIVO 20 containing various concentrations of recombinant 
human CCL19 (Biolegend) was added to the bottom chambers, 
and 5 × 104 NK cells in 100 μl of serum-free X-VIVO 20 media 
without CCL19 was added to the top chambers. The plate was 
incubated for 2 h at 37°C in 5% CO2 before transwell membranes 
were removed and cells in the bottom chamber were harvested. 
The amount of migrated cells was quantified on a Wallac 1420 
Microplate Reader (Perkin Elmer) using the CyQUANT kit 
(Life Technologies). Cells plated straight to the bottom chamber 
were used as maximum control, and the proportion of migrated 
cells was calculated as a percent of total cells initially added to 
each well.
nK cell Degranulation assay
Natural killer cells were cocultured with 721.221 cells at a ratio 
of 1:1 in 96-well plates at 37°C and 5% CO2 with or without 
rituximab. After 1 h, cells were stained with cell surface mAbs 
and a viability marker for 15 min on ice, followed by washes and 
fixation in 1% paraformaldehyde (MP Biomedicals) in PBS. Cells 
were acquired on a BD LSR II Fortessa.
Data and statistical analysis
Flow cytometry data were analyzed using the FlowJo software 
(Treestar, Inc.). Graphs and statistical analyses were performed 
with GraphPad PRISM (GraphPad Software, Inc.). *p < 0.05 and 
**p < 0.01.
resUlTs
high Transfection efficacy following 
mrna electroporation of nK cells without 
compromising Their Viability and Function
We first set out to evaluate the transfection efficacy, viability, 
proliferation, and function of ex vivo-expanded NK cells 
following mRNA electroporation. Using the scalable cGMP-
compliant MaxCyte GT transfection system and expanded NK 
cells utilizing methods from our ongoing phase I clinical trial, 
we observed highly reproducible rapid GFP protein expres-
sion in nearly 100% of eGFP mRNA-electroporated NK cells 
(Figure  1A). GFP expression was detectable in proliferating 
NK cells for up to 3 weeks, with expression in >95% of cells 
for the first 7–9 days after gene delivery and had no deleterious 
effects on cell viability. Since GFP represents an intracellular 
molecule with a long half-life, we also evaluated the capac-
ity of this transfection technique to induce expression of 
selected molecules on the surface of NK cells. Electroporation 
of NK cells with mRNA coding for the cell surface marker 
CD34 led to surface expression for up to 7  days, with peak 
expression occurring approximately 24 h after electroporation 
(Figure 1B). As with GFP, no significant impact on viability 
was observed following electroporation. Although elec-
troporated NK cells maintained their capacity to proliferate 
in  vitro, there was a slight delay in the start of proliferation 
after electroporation compared to non-electroporated controls 
(Figure 1C). Importantly, NK cell cytotoxicity, as assessed by 
their ability to kill K562 cells and the multiple myeloma cell 
line MM.1S, remained high and was unaffected by electropo-
ration compared to controls (Figure 1D).
mrna electroporation of nK cells Does 
not significantly alter the expression of 
nK cell surface receptors
As electroporation of NK cells potentially could lead to 
unintended phenotypic alternations that perturb NK cell 
activation and target specificity, we next performed high-
resolution flow cytometry to evaluate the phenotype of CD34 
mRNA-electroporated NK cells compared to controls. With the 
exception of slight decreases in NKp30, 2B4, and TRAIL, there 
was no significant alteration in the surface expression of any 
of the 15 activating and inhibitory NK cell receptors in CD34 
mRNA-electroporated NK cells compared to controls 24  h 
after electroporation (Figure 2). Daily flow cytometry analysis 
showed no additional phenotypic changes occurred during the 
first 6 days following electroporation with CD34 mRNA (data 
not shown).
reprograming of nK cells with the 
chemokine receptor ccr7 improves 
Their ability to Migrate Toward the ccr7 
ligand ccl19
The use of mRNA electroporation to genetically engineer NK 
cells to improve their homing capacity has not previously been 
studied. Therefore, we next electroporated NK cells with mRNA 
coding for the chemokine receptor CCR7, which is known to 
direct cellular migration to secondary lymphoid tissues, includ-
ing lymph nodes where hematological malignancies such as 
lymphoma reside. The CCR7 receptor is normally expressed by 
only a small subset of primary NK cells (primarily the CD56bright 
NK cell subset), with expression completely disappearing 
following ex vivo expansion. By electroporating expanded 
NK cells with increasing concentrations of CCR7 mRNA, 
a correlation between mRNA dose and CCR7 cell surface 
expression was established (Figures 3A,B). Using 4-μg CCR7 
mRNA per million NK cells, cell surface expression of CCR7 
was sustained for up to 48  h with peak expression measured 
8 h following electroporation (Figure 3C). Except for increased 
TRAIL expression, no changes in NK cell receptor expres-
sion were observed on CCR7 mRNA-electroporated NK cells 
compared to their non-electroporated counterparts (Figure S1 
in Supplementary Material). Moreover, as with CD34 mRNA-
electroporated NK cells, NK cells electroporated with CCR7 
mRNA maintained potent cytotoxicity function against tumor 
cells (Figure S2 in Supplementary Material). Importantly, CCR7 
mRNA-electroporated NK cells showed marked dose depend-
ent in vitro migration capacity toward the CCL19 chemokine 
(Figure 3D), in contrast to non-electroporated NK cells, which 
lacked CCL19-specific migration. As reported for other CCR7-
expressing lymphocytes, exposure of CCR7 mRNA-electropo-
rated NK cells to CCL19 led to a dose-dependent reduction 
of cell surface CCR7 expression (Figure S3 in Supplementary 
Material) (7), indicating that the transfected receptor behaved 
similar to wild-type CCR7.
FigUre 1 | characterization of clinical-grade ex vivo-expanded human nK cells electroporated with gFP and cD34 mrna. Ex vivo-expanded NK cells 
were electroporated with mRNA coding for GFP or CD34 using the MaxCyte GT instrument. Transgene expression, viability, and proliferative and cytotoxic capacity 
were measured over time using flow cytometry. (a) GFP expression and viability (determined by Annexin V and 7-AAD from Becton Dickinson) of ex vivo-expanded 
NK cells from healthy donors following electroporation with 0.25 μg of eGFP mRNA (TriLink Biotechnology) per million NK cells. (B) CD34 expression (determined by 
anti-CD34 antibody staining) and viability of NK cells expanded from three healthy donors following electroporation with 1 μg of CD34 mRNA (TriLink Biotechnology) 
per million NK cells. (c) Fold expansion of NK cells ex vivo following CD34 mRNA electroporation compared to non-electroporated NK cells. (D) Specific lysis of 
K562 cells and the multiple myeloma cell line MM.1S by CD34 mRNA-electroporated and non-electroporated NK cells. Non-EP, non-electroporated; GFP-EP, eGFP 
mRNA electroporated; CD34-EP, CD34 mRNA electroporated. A Wilcoxon ranked sum t-test was used in (a,B), whereas a paired t-test was used in (c).
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FigUre 2 | Phenotypic characterization of clinical-grade ex vivo-expanded nK cells following mrna electroporation. Expression of activating and 
inhibitory NK cell receptors on ex vivo-expanded NK cells was assessed 24 h after electroporation with CD34 mRNA (1 μg/million NK cells) using the MaxCyte GT 
instrument. (a) Representative histograms for one NK cell donor and pooled data from three donors showing the relative expression intensity of selected NK cell 
receptors on electroporated compared to non-electroporated ex vivo-expanded NK cells. (B) Representative dot plots for one NK cell donor and pooled data from 
three donors showing expression of clonally expressed NK cell receptors on electroporated and non-electroporated NK cells from three healthy donors. Non-EP, 
non-electroporated; CD34-EP, CD34 mRNA electroporated.
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FigUre 3 | ccr7 expression and migration capacity of clinical-grade ex vivo-expanded nK cells electroporated with ccr7 mrna. Ex vivo-expanded 
NK cells were electroporated with mRNA coding for the homing receptor CCR7 using the MaxCyte GT instrument. (a) Representative example of CCR7 expression 
on NK cells 8 h after electroporation with CCR7 mRNA (CCR7-EP) compared to non-electroporated (non-EP) NK cells. (B) Correlation between CCR7 expression 
and CCR7 mRNA dose (line; linear regression). (c) Kinetics of CCR7 expression on NK cells following electroporation with 4 μg/million NK cells. Error bars, SEM.  
(D) Transwell migration of non-EP and CCR7-EP NK cells against a gradient of CCL19 (a ligand for CCR7). Error bars, SEM. A paired t-test was used in (c,D).
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augmented nK cell aDcc by introduction 
of the high-affinity cD16-158V receptor
To establish whether this cGMP-complaint transfection tech-
nique could also be used to improve NK cell cytotoxicity, NK 
cells obtained from CD16-158F/F donors were transfected with 
mRNA coding for the high-affinity Fc receptor CD16-158V in 
an effort to augment their capacity to induce ADCC against 
rituximab-coated CD20+ B cell lymphoma cells. As shown in 
Figure 4A, 24 h following the electroporation of NK cells with 
CD16-158V mRNA, cell surface expression of CD16 increased 
significantly compared to non-electroporated controls. As for 
CD34 and CCR7 mRNA-electroporated NK cells, no major 
changes in NK cell receptor expression was observed on NK 
cells electroporated with CD16-158V mRNA (Figure S1 in 
Supplementary Material). Kinetic studies showed CD16 expres-
sion on electroporated cells remained at higher levels than 
controls for up to 72 h following electroporation. In line with 
these phenotypic changes, CD16-158V mRNA-electroporated 
NK cells acquired an enhanced ability to mediate ADCC when 
cocultured with rituximab-coated EBV-transformed B-cell 
lymphoma cells compared to controls (Figures  4B,E). This 
enhanced killing effect against rituximab-treated tumor cells 
persisted for up to 3 days following electroporation (Figure 4B). 
By conducting experiments where NK cells were loaded with 
different concentrations of the CD16-158V mRNA, we observed 
that both CD16 expression and ADCC were CD16-158V mRNA 
dose dependent (Figures  4C,D). Importantly, electropora-
tion of NK cells with CD16-158V mRNA did not affect their 
baseline (non-ADCC-mediated) cytotoxic function (Figure S2 
in Supplementary Material). Taken altogether, these data estab-
lish mRNA electroporation as a rapid, efficient, and non-toxic 
method to genetically modify ex vivo-expanded NK cells to 
improve their tumor homing capacity and antitumor cytotoxic 
function.
DiscUssiOn
Here, we show that mRNA electroporation is a highly efficient 
method to genetically reprogram multiple NK cell modalities 
without incurring any deleterious effects on their viability, phe-
notype, and function. The data presented in this report provide a 
foundation for strategies that incorporate mRNA electroporation 
into clinical trials utilizing adoptive NK cell immunotherapy. The 
electroporation system used in these experiments on NK cells is 
ideally suited for use in the clinic, having the capacity to transfect 
extremely large numbers of cells (up to 2 ×  1010 cells) in only 
FigUre 4 | cD16 expression and aDcc capacity of clinical-grade ex vivo-expanded nK cells electroporated with cD16-158V mrna. Ex vivo-expanded 
NK cells were electroporated with mRNA coding for the high-affinity Fc receptor CD16-158V using the MaxCyte GT instrument. (a) Representative example and 
average cell surface expression of CD16 on NK cells 24 h after electroporation with CD16 mRNA (CD16-EP) compared to non-electroporated (non-EP) NK cells 
(n = 7) as well as kinetics of CD16 surface expression following electroporation (n = 3) Error bars, SEM. (B) NK cell degranulation (measured by CD107a expression) 
by CD16-158V mRNA-electroporated NK cells compared to non-EP NK cells following coculture with CD20+ 721.221 EBV–LCL cells in the absence (no mAb, no 
monoclonal antibody) and presence of rituximab (RTX) 24 h after electroporation (n = 7) as well as kinetics of NK cell ADCC following electroporation (n = 3). Error 
bars, SEM. (c) Correlation between CD16 expression and CD16-158V mRNA dose [line; variable slope log (agonist) vs. response regression]. (D) Correlation 
between NK cell CD16 expression and ADCC capacity against rituximab-treated 721.221 EBV–LCL (line; linear regression). (e) Specific lysis of CD20+ 721.221  
EBV–LCL cells by CD16-158V mRNA-electroporated NK cells compared to non-EP NK cells [as measured in a 51Cr-release assay (CRA) 24 h after electroporation] in 
the absence (no mAb, no monoclonal antibody) and presence of rituximab (RTX) at a 0.5:1 ratio of NK cells to EBV–LCL targets. Error bars, SD. Wilcoxon ranked sum 
t-tests were used in the bar graphs in (a,B), whereas paired t-tests were used for statistics in the graphs showing kinetics of CD16 expression and NK cell ADCC.
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20  min under GMP conditions. Finally, the recent use of this 
system in clinical trials of dendritic cell vaccine and T cell-based 
cancer therapies further highlights the ready applicability of 
mRNA electroporation into NK cell-based immunotherapy trials 
(8, 9).
Compared to viral transduction, mRNA electroporation 
results in relatively transient protein expression. In this con-
text, variability in the half-life of proteins as well as variability 
in membrane turnover and receptor internalization are the 
factors that regulate surface expression time for specific trans-
fected proteins. Modifications of the mRNA, such as capping, 
poly(A) elongation, and use of pseudouridine instead of uridine 
nucleotides, may all be used to prolong the time of transgene 
expression. However, it is important to consider that adoptively 
infused NK cells can mediate rapid antitumor responses while 
persisting for relatively short periods compared to adoptively 
transferred T cells. Therefore, stable transgene expression in 
these cells may not be necessary. Indeed, the short-lived and 
non-integrating nature of mRNA may be advantageous in situ-
ations where new transgenes are being tested for the first time 
in patients, as this approach potentially minimizes the risk of 
uncontrollable adverse events, which have been observed to 
occur following the infusion of stably transduced T cells (10, 
11). The development of methods that expand large numbers of 
NK cells ex vivo from the blood of cancer patients now provides 
a clinical scenario, where repeated infusions of genetically 
modified NK cells can be used to improve the efficacy of adop-
tive NK cell transfer while reducing risks related to unexpected 
side effects (3).
The availability of the GMP-compliant platform described 
herein offers a method to explore a wide range of genetic 
manipulations to promote NK cell-based cancer immunother-
apy. Genetic manipulation of NK cells to target tumors through 
expression of chimeric antigen receptors (CARs) represents 
one of the more attractive clinical uses of this approach (7, 12). 
As previously demonstrated (2, 6), NK cells electroporated with 
mRNA coding for an anti-CD19 CAR acquired augmented 
cytotoxicity against B cell malignancies both in  vitro and in 
a preclinical animal model. Our data suggest that mRNA 
electroporation could also be used to augment the ability of 
adoptively transferred NK cells more globally by enhancing 
their ability to mediate ADCC in patients with cancer who are 
receiving treatment with monoclonal antibodies. In the clinic, 
it has been recognized that lymphoma patients homozygous for 
the CD16-158V polymorphism, encoding for a high-affinity IgG 
antibody-binding receptor, have substantially higher response 
rates following treatment with the anti-CD20 antibody rituxi-
mab compared to those who carry the low-affinity CD16-158F 
polymorphism (13–16). Preclinical data presented in this study 
suggest the infusion of ex vivo-expanded NK cells electroporated 
to express the CD16-158V receptor could enhance antibody-
mediated antitumor responses through ADCC. This approach 
is appealing not only because a minority of patients are homozy-
gous for the CD16-158V polymorphism but also since infusions 
of CD16-158V electroporated NK cells could be used to improve 
the efficacy of virtually any malignancy for which there is an 
FDA approved IgG1 antibody.
Another group of receptors that could be modified to improve 
outcomes following NK cell-based cancer immunotherapy are 
homing receptors. Based on preclinical mouse data showing 
improved lymph node homing of CCR7-overexpressing NK 
cells (17) along with data presented in this study, electropora-
tion of NK cells with mRNA coding for CCR7 is a candidate 
strategy to study in patients with lymphoma as well as in 
patients who have tumors metastasized to lymphoid tissues. 
If combined with CD16 mRNA electroporation, this approach 
could theoretically be used to improve the ability of adoptively 
transferred NK cells to both home to tumor cells residing in 
lymphoid tissues and kill these lymphoid residing tumor cells 
via augmented NK cell ADCC following monoclonal antibody 
treatment.
Other applications for this technology include reprograming 
of NK cells by electroporation of mRNA coding for transcription 
factors or by combining it with the CRISPR/Cas9 technology, 
whereby guiding RNAs together with mRNA coding for the 
endonuclease Cas9 are introduced to silence genes by inducing 
DNA double-strand breaks. The latter can be used to permanently 
deplete genes coding for inhibitory receptors expressed on NK 
cells, such as programed cell death-1 (PD-1), thereby increasing 
their tumor-targeting capacity.
In conclusion, these studies establish mRNA electroporation 
to be a highly efficient method to express transgenes in ex vivo-
expanded clinical-grade NK cells without incurring any negative 
effects on their phenotype and antitumor function. The avail-
ability of this platform offers a novel, rapid, and efficient strategy 
to genetically manipulate NK cells and opens up numerous new 
possibilities to advance the field of NK cell-based cancer immu-
notherapy. Future clinical trials studying the adoptive infusion 
of NK cells genetically reprogramed to more efficiently home to 
tumor-bearing tissues and thereby better recognize and kill the 
tumor cells will soon shed light on the potential of this approach 
in patients with cancer.
aUThOr cOnTriBUTiOns
MC: design, experiments, data analysis, figures, and manuscript 
writing; EL, AK, LL, and RR: experiments and manuscript review; 
MB and MP: manuscript review; and RC: design and manuscript 
writing.
FUnDing
This research was supported by the Intramural Research Program 
at the National Heart, Lung, and Blood Institute, National 
Institutes of Health.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fimmu.2016.00105
9Carlsten et al. Reprogramming NK-Cells Using mRNA Electroporation
Frontiers in Immunology | www.frontiersin.org March 2016 | Volume 7 | Article 105
reFerences
1. Miller JS, Soignier Y, Panoskaltsis-Mortari A, Mcnearney SA, Yun GH, 
Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human 
haploidentical NK cells in patients with cancer. Blood (2005) 105:3051–7. 
doi:10.1182/blood-2004-07-2974 
2. Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, et al. Expression 
of chimeric antigen receptors in natural killer cells with a regulatory-com-
pliant non-viral method. Cancer Gene Ther (2010) 17:147–54. doi:10.1038/
cgt.2009.61 
3. Childs RW, Berg M. Bringing natural killer cells to the clinic: ex vivo manip-
ulation. Hematology Am Soc Hematol Educ Program (2013) 2013:234–46. 
doi:10.1182/asheducation-2013.1.234 
4. Childs RW, Carlsten M. Therapeutic approaches to enhance natural killer cell 
cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov (2015) 
14:487–98. doi:10.1038/nrd4506 
5. Carlsten M, Childs RW. Genetic manipulation of NK cells for cancer immu-
notherapy: techniques and clinical implications. Front Immunol (2015) 6:266. 
doi:10.3389/fimmu.2015.00266 
6. Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T, Eldridge P, et al. A 
clinically adaptable method to enhance the cytotoxicity of natural killer cells 
against B-cell malignancies. Cytotherapy (2012) 14:830–40. doi:10.3109/1465
3249.2012.671519 
7. Byers MA, Calloway PA, Shannon L, Cunningham HD, Smith S, Li F, et al. 
Arrestin 3 mediates endocytosis of CCR7 following ligation of CCL19 but not 
CCL21. J Immunol (2008) 181:4723–32. doi:10.4049/jimmunol.181.7.4723 
8. Dannull J, Haley NR, Archer G, Nair S, Boczkowski D, Harper M, et  al. 
Melanoma immunotherapy using mature DCs expressing the constitutive 
proteasome. J Clin Invest (2013) 123:3135–45. doi:10.1172/JCI67544 
9. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et  al. 
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells 
induce anti-tumor activity in solid malignancies. Cancer Immunol Res (2014) 
2:112–20. doi:10.1158/2326-6066.CIR-13-0170 
10. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. 
Case report of a serious adverse event following the administration of T cells 
transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 
(2010) 18:843–51. doi:10.1038/mt.2010.24 
11. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et  al. Efficacy 
and toxicity management of 19-28z CAR T cell therapy in B cell acute 
lymphoblastic leukemia. Sci Transl Med (2014) 6:224ra225. doi:10.1126/
scitranslmed.3008226 
12. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of 
therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 
(2014) 257:107–26. doi:10.1111/imr.12131 
13. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel 
polymorphism of FcgammaRIIIa (CD16) alters receptor function and predis-
poses to autoimmune disease. J Clin Invest (1997) 100:1059–70. doi:10.1172/
JCI119616 
14. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymor-
phisms independently predict response to rituximab in patients with follicular 
lymphoma. J Clin Oncol (2003) 21:3940–7. doi:10.1200/JCO.2003.05.013 
15. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby 
E, et  al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are 
associated with clinical response to rituximab in Waldenstrom’s macroglobu-
linemia. J Clin Oncol (2005) 23:474–81. doi:10.1200/JCO.2005.06.059 
16. Pander J, Gelderblom H, Antonini NF, Tol J, Van Krieken JH, Van Der Straaten 
T, et  al. Correlation of FCGR3A and EGFR germline polymorphisms with 
the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur 
J Cancer (2010) 46:1829–34. doi:10.1016/j.ejca.2010.03.017 
17. Somanchi SS, Somanchi A, Cooper LJ, Lee DA. Engineering lymph node 
homing of ex vivo-expanded human natural killer cells via trogocytosis of 
the chemokine receptor CCR7. Blood (2012) 119:5164–72. doi:10.1182/
blood-2011-11-389924 
Conflict of Interest Statement: LL and MP are employees of MaxCyte, Inc. The 
remaining authors have no conflicts of interest to declare.
Copyright © 2016 Carlsten, Levy, Karambelkar, Li, Reger, Berg, Peshwa and Childs. 
This is an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) or licensor are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
